Khả năng làm giảm độc tính do hóa trị và cải thiện các triệu chứng phế nham thể khí âm lưỡng hư của cao UP1

Abstract

Objective: To evaluate the ability of UP1 extract to reduce clinical and paraclinical toxicities associated with the Paclitaxel–Carboplatin regimen, and to improve symptoms of Qi and Yin dual deficiency in patients with lung cancer.

Subjects and methods: The study included 60 patients diagnosed with stage IIIB-IV non-small cell lung cancer, divided into two groups of 30 patients each. The study group received Paclitaxel-Carboplatin chemotherapy combined with 90 ml/day of UP1 extract, while the control group received only Paclitaxel-Carboplatin chemotherapy. Treatment duration was 21 days per cycle for 3 cycles. Pre- and post-treatment outcomes were compared within and between the treatment groups. 

Results: In clinical: Nausea and vomiting were significantly less frequent in the study group than in the control group (p<0.05). In paraclinical: The incidence of leukopenia was significantly reduced in the study group (p<0.05). There were no significant differences between the groups in terms of hemoglobin decrease, thrombocytopenia, or elevations in bilirubin, AST, ALT levels (p>0.05). No nephrotoxicity was observed in either group. Symptoms of Qi and Yin dual deficiency such as fatigue, shortness of breath, and weak pulse: Showed marked improvement in the study group after therapy (p<0.05).

Conclusion: UP1 extract helps reduce nausea and vomiting, mitigates leukopenia induced by the Paclitaxel-Carboplatin regimen, and improves symptoms of the Qi and Yin dual deficiency.